There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Thermo Fisher (TMO – Research Report), Conmed (CNMD – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments.
Thermo Fisher (TMO)
Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Thermo Fisher on April 26 and set a price target of $600.00. The company’s shares closed last Tuesday at $568.72.
According to TipRanks.com, Arias has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $628.67, which is a 9.4% upside from current levels. In a report issued on April 17, HSBC also maintained a Buy rating on the stock with a $660.00 price target.
See today’s best-performing stocks on TipRanks >>
Conmed (CNMD)
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Conmed on April 26 and set a price target of $88.00. The company’s shares closed last Tuesday at $67.98, close to its 52-week low of $61.05.
According to TipRanks.com, Wise is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Conmed with a $87.83 average price target, which is a 31.9% upside from current levels. In a report issued on April 25, Needham also maintained a Buy rating on the stock with a $107.00 price target.
BioMarin Pharmaceutical (BMRN)
In a report issued on April 26, Paul Matteis from Stifel Nicolaus maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $108.00. The company’s shares closed last Tuesday at $80.76.
According to TipRanks.com, Matteis is a 4-star analyst with an average return of
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $111.33, implying a 36.1% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Buy rating on the stock with a $140.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TMO:
- Bio-Techne announces new distribution agreement with Thermo Fisher
- Thermo Fisher price target raised to $610 from $600 at Deutsche Bank
- Thermo Fisher price target raised to $662 from $657 at RBC Capital
- Thermo Fisher price target raised to $648 from $644 at TD Cowen
- Thermo Fisher price target raised to $650 from $600 at JPMorgan
